Overgrowth syndromes: Evaluation and management of the child with excessive linear growth

Pediatric Endocrinology, Fifth Edition: Volume 2 Growth, Adrenal, Sexual, Thyroid, Calcium, and Fluid Balance Disorders

Volumn , Issue , 2006, Pages 163-194

  Root, Allen W ^a,b   Diamond, Frank B ^a,b  

^a JOHNS HOPKINS ALL CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 41349090258     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (256)

1. Cohen MM Jr. Overgrowth syndromes: an update. Adv Pediatr 1999; 46:441-491.
2. Hamilton WJ, Mossman HW. Human Embryology; Prenatal Development of Form and Function. 4th ed. Baltimore: Williams and Wilkins, 1972:1-646.
3. Sparks JW. Intrauterine growth and nutrition. In: Polin RA, Fox WN, eds. Fetal and Neonatal Physiology. 2nd. Philadelphia: WB Saunders, 1998:267-289.
4. Underwood LE, VanWyk JJ.Normal and abnormal growth. In: Wilson JD, Foster DW, eds. Williams Textbook of Endocrinology. 8th ed. Philadelphia, 1992:1079-1138.
5. Diamond FB. Fetal growth programs future health: causes and consequences of intrauterine growth retardation. In: Barness LA, ed. Adv Pediatr. 2001; 48:245-272.
6. Massa G, de Zegher F, Vanderschueren-Lodeweyckx M. Serum growth hormone binding protein in the human fetus and infant. Pediatr Res 1992; 32:69-72.
7. Gluckman PD. The endocrine regulation of fetal growth in late gestation: the role of insulin-like growth factors. J Clin Endocrinol Metab 1995; 80:1047-1050.
8. Palmiter RD, Norstedt G, Gelinas RE, et al. Metallothionein-human GH fusion genes stimulate growth of mice. Science 1983; 222:809-814.
9. McIntyre HD, Serek R, Crane DI, et al. Placental growth hormone (GH), GH-binding protein, and insulin-like growth factor axis in normal, growth retarded, and diabetic pregnancies: correlations with fetal growth. J Clin Endocrinol Metab 2000; 85:1143-1150.
10. Caufriez A, Frankeene F, Hennen G, et al. Regulation of maternal IGF-1 by placental GH in normal and abnormal human pregnancies. Am J Physiol 1993; 265: E572-E577.
11. Lassare C, Hardouin S, Daffos F, et al. Serum insulin-like growth factors and insulin-like growth factor binding proteins in the human fetus: relationships with growth in normal subjects and in subjects with intrauterine growth retardation. Pediatr Res 1991; 29:219-225.
12. Mirlesse V, Frankeene F, Alsat E, et al. Placental growth hormone levels in normal pregnancy and in pregnancies with intrauterine growth retardation. Pediatr Res 1993; 34:439-442.
13. Gluckman PD. Endocrine and nutritional regulation of prenatal growth. Acta Paediatr Suppl 1997; 423:153-157.
14. Guidice LC, de Zehger F, Gargosky SE, et al. Insulin-like growth factors and their binding proteins in the term and preterm human fetus and neonates with normal and extremes of intrauterine growth. J Clin Endocrinol Metab 1995; 80:1548-1555.
15. D’Ercole AJ. Mechanisms of in utero overgrowth. Acta Paediatr Suppl 1999; 428:31-36.
16. Gluckman PD, Butler JH, Comline R, et al. The effects of pancreatectomy on the plasma concentrations of insulinlike growth factors l and 2 in the sheep fetus. J Dev Physiol 1987; 9:79-88.
17. Accili D, Nakae J, Kim JJ, et al. Targeted gene mutations define the roles of insulin and IGF-1 receptors in mouse embryonic development. J Pediatr Endocrinol Metab 1999; 12:475-485.
18. Liu JL, Yakar S, Le Roith D. Conditional knockout of mouse insulin-like growth factor Bi gene using the Cre/lox P system. Proc Soc Exp Biol Med 2000; 223:344-351.
19. Abuzzahab MJ, Schneider A, Goddard A, et al. IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation. N Engl J Med 2003; 349:2211-2222.
20. Kawashima Y, Kanzaki S, Yang F, et al. Mutation at cleavage site of insulin-like growth factor receptor in a short stature child with intrauterine growth retardation. J Clin Endocrinol Metab 2005; 90:4679-4687.
21. Sun F-L, Dean WL, Kelsey G, et al. Transactivation of IGF2 in a mouse model of Beckwith-Wiedemann syndrome. Nature 1997; 389:809-815.
22. Ludwig T, Eggenschwiler J, Fisher P, et al. Mouse mutants lacking the type 2 IGF receptor (IGFR2) are rescued from perinatal lethality in Igf2 and Igflr null backgrounds. Dev Biol 1996; 177:517-535.
23. Leighton PA, Ingram RS, Eggenschwiler J, et al. Disruption of imprinting caused by deletion of the H19 gene region in mice. Nature 1995; 375:16-17.
24. Tanner JM. Normal growth and techniques of growth assessment. Clin Endocrinol Metab NA 1986; 15: 411-451.
25. Dewey KG. Growth characteristics of breast-fed compared to formula fed infants. Biol Neonate 1998; 74: 94-105.
26. Lampl M, Veldhuis JD, Johnson ML. Saltation and stasis: a model of human growth. Science 1992; 258:801-803.
27. Lampl M, Thompson AL, Frongillo EA. Sex differences in the relationships among weight gain, subcutaneous skinfold tissue and saltatory length growth spurts in infancy. Pediatr Res 2005; 58:1238-1242.
28. Smith DW, Truog W, Rogers JE, et al. Shifting linear growth during infancy: illustration of genetic factors in growth from fetal life through infancy. J Pediatr 1976; 89:225-230.
29. Ong KKL, Ahmed ML, Emmett PM, et al. Association between postnatal catch-up growth and obesity in childhood: prospective cohort study. BMJ 2000; 320:967-971.
30. Mei Z, Grummer-Strawn LM, Thompson D, Dietz WH. Shifts in percentiles of growth during early childhood: analysis of longitudinal data from California Child Health and Developmental Study. Pediatrics 2004; 113:e617-e627. Available at http//www.pediatrics.org/cgi/content/full/aa3/6/e617.
31. Stettler N, Zemel BS, Kumanyika S, et al. Infant weight gain and childhood overweight status in a multicenter cohort study. Pediatrics 2002; 109:194-199.
32. Phillip M, Lazar L. The regulatory effect of hormones and growth factors on the pubertal growth spurt. Endocrinologist 2003; 13:465-469.
33. Liu MC, Marshall JL, Pestell RG. Novel strategies in cancer therapeutics: targeting enzymes involved in cell cycle regulation and cellular proliferation. Curr Cancer Drug Targets 2004; 4:403-424.
34. Nusinzon I, Horvath CM. Histone deacetylases as transcriptional activators? Role reversal in inducible gene regulation. Sci STKE 2005; re11.
35. Fu M, Wang C, Li Z, et al. Minireview: Cyclin D1: normal and abnormal functions. Endocrinology 2004; 145: 5439-5447.
36. Bartek J, Lukas J. Order from destruction. Science 2001; 294:66-67.
37. Jiang Y-h, Beaudet AL. Human disorders of ubiquitination and proteasomal degradation. Curr Opin Pediatr 2004; 16:419-426.
38. Bettencourt-Dias M, Glet R, Sinka R, et al. Genome-wide survey of protein kinases required for cell cycle progression. Nature 2004; 432:980-987.
39. Yamaguchi A, Komori T, Suda T. Regulation of osteoblast differentiation mediated by bone morphogenetic proteins, hedgehogs, and Cbfa1. Endocrine Rev 2000; 21:383-411.
40. Pawson T, Nash P. Assembly of cell regulatory systems through protein interaction domains. Science 2003; 300:445-452.
41. Van der Eerden BCJ, Karperien M, Wit JM. Systemic and local regulation of the growth plate. Endocrine Rev 2003; 24:782-801.
42. Robson H, Siebler T, Shalet SM, Williams GR. Interactions between GH, IGF-I, glucocorticoids, and thyroid hormones during skeletal growth. Pediatr Res 2002; 52:137-147.
43. Ornitz DM. FGF signaling in the developing endochondral skeleton. Cytokine Growth Factor Rev 2005; 16: 205-213.
44. Thiel CT, Horn D, Zabel B, et al. Severely incapacitating mutations in patients with extreme short stature identify RNA-processing endoribonuclease RMRP as an essential growth regulator. Am J Hum Genet 2005; 77:795-806.
45. Laron Z. IGF-1 and insulin as growth hormones. Novartis Found Symp 2004; 262:56-77.
46. Yakar S, Rosen CJ, Beamer WG, et al. Circulating levels of IGF-I directly regulate bone growth and density. J Clin Invest 2002; 110:771-781.
47. Cruickshank J, Grossman DJ, Peng RK, et al. Spatial distribution of growth hormone receptor, insulin-like growth factor-1 and apoptotic chondrocytes during growth plate development. J Endocrinol 2005; 184:543-553.
48. Wang J, Zhou J, Cheng CM, et al. Evidence supporting dual, IGF-I-independent and IGF-I-dependent, roles for GH in promoting longitudinal bone growth. J Endocrinol 2004; 180:247-255.
49. Bottcher RT, Niehrs C. Fibroblast growth factor signaling during early vertebrate development. Endocrine Rev 2005; 26:63-77.
50. Caminos JE, Gualillo O, Lago F, et al. The endogenous growth hormone secretagogue (Ghrelin) is synthesized and secreted by chondrocytes. Endocrinology 2005; 146:1285-1292.
51. Kume K, Satomura K, Nishisho S, et al. Potential role of leptin in endochondral ossification. J Histochem Cytochem 2002; 50:159-169.
52. Figenschau Y, Knutsen G, Shahazeydi S, et al. Human articular chondrocytes express functional leptin receptors. Biochem Biophys Res Comm 2001; 287:190-197.
53. Terlain B, Dumond H, Presle N, et al. Is leptin the missing link between osteoarthritis and obesity? Ann Pharmaceut Franc 2005; 63:186-193.
54. Ballock RT, Zhou X, Mink LM, et al. Expression of cyclindependent kinase inhibitors in epiphyseal chondrocytes induced to terminally differentiate with thyroid hormone. Endocrinology 2000; 141:4552-4557.
55. Colombani J, Bianchini L, Layalle S, et al. Antagonistic actions of ecdysone and insulins determine final size in Drosophila. Science 2005; 310:667-670.
56. Gennari L, Nuti R, Bilezikian JP. Aromatase activity and bone homeostasis in men. J Clin Endocrinol Metab 2004; 89:5898-5907.
57. Grumbach MM. Estrogen, bone, growth, and sex: a sea change in conventional wisdom. J Pediatr Endocrinol Metab 2001; 13:1439-1455.
58. Eastell R. Role of estrogen in the regulation of bone turnover at the menarche. J Endocrinol 2005; 185:223-234.
59. Ergerbacher M, Helmreich M, Rossmanith W, Haeusler G. Estrogen receptor-alpha and estrogen receptor-beta are present in the human growth plate in childhood and adolescence in identical distribution. Horm Res 2002; 58:99-103.
60. Nilsson O, Chrysis D, Pajulo O, et al. Localization of estrogen receptors-alpha and -beta and androgen receptor in the human growth plate at different pubertal stages. J Endocrinol 2003; 177:319-326.
61. Chagin AS, Lindberg MK, Andersson N, et al. Estrogen receptor-beta inhibits skeletal growth and has the capacity to mediate growth plate fusion in female mice. J Bone Miner Res 2004; 19:72-77.
62. Vanderscheuren D, Vandenput L, Boonen S, et al. Androgens and bone. Endocrine Rev 2004; 25:389-425.
63. Noble B, Routledge J, Stevens H, et al. Androgen receptors in bone-forming tissue. Horm Res 1999; 51:31-36.
64. Krohn K, Haffner D, Hugel U, et al. 1,25(OH)2D3 and dihydrotestosterone interact to regulate proliferation and differentiation of epiphyseal chondrocytes. Calc Tiss Intern 2003; 73:400-410.
65. Strewler GJ. The physiology of parathyroid hormonerelated protein. N Engl J Med 2000; 342:177-645.
66. Liu Y-Z, Xu F-H, Shen H, et al. Genetic dissection of human stature in a large sample of multiplex pedigrees. Ann Hum Genet 2004; 68:472-488.
67. Raynaud M, Ronce N, Ayrault AD, et al. X-linked mental retardation with isolated growth hormone deficiency is mapped to Xq22-Xq27.2 in one family. Am J Med Genet 1998; 76:255-261.
68. Woods KS, Cundall M, Turton J, et al. Over-and underdosage of SOX3 is associated with infundibular hypoplasia and hypopituitarism. Am J Hum Genet 2005; 76:833-849.
69. Hasegawa Y, Fujii K, Yamada M, et al. Identification of novel human GH-1 gene polymorphisms that are associated with growth hormone secretion and height. J Clin Endocrinol Metab 2000; 85:1290-1295.
70. Van Heemst D, Beekman M, Mooijaart SP, et al. Reduced insulin/IGF-I signaling and human longevity. Aging Cell 2004; 4:79-85.
71. Dos Santos C, Essioux L, Teinturier C, et al. A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone. Nat Genet 2004; 36:720-724.
72. Teinturier C, Dos Santos C, Bougneres P. The growth hormone receptor polymorphism influences the response of severely growth hormone deficient children to growth hormone treatment. 87th Annual Meeting of the Endocrine Society, San Diego, CA, 2005, P2-P481 (Abstract).
73. Blair JC, Savage MO. The GH-IGF-I axis in children with idiopathic short stature. Trends Endocrinol Metab 2002; 13:325-330.
74. Goddard AD, Covello R, Luoh S-M, et al. Mutations of the growth hormone receptor associated with idiopathic short stature. N Engl J Med 1995; 333:1093-1098.
75. Bonopace G, Concolino D, Formicola S, Strisciuglio P. A novel mutation in a patient with insulin-like growth factor 1 (IGF1) deficiency. J Med Genet 2003; 40:913-917.
76. Woods KA, Camacho-Hubner C, Savage MO, Clark AJ. Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. N Engl J Med 1996; 335:1363-1367.
77. Arends N, Johnston L, Hokken-Koelega A, et al. Polymorphism in the IGF-I gene: clinical relevance for short children born small for gestational age (SGA). J Clin Endocrinol Metab 2002; 87:2720-2724.
78. Peeters RP, van den Beld AW, van Toor H, et al. A polymorphism in type I deiodinase is associated with circulating free insulin-like growth factor I levels and body composition in humans. J Clin Endocrinol Metab 2005; 90:256-263.
79. Shavlakadze T, Winn N, Rosenthal N, Grounds MD. Reconciling data from transgenic mice that overexpress IGF-I specifically in skeletal muscle. Growth Horm IGF Res 2005; 15:4-18.
80. Clemmons DR, Maile LA. Minireview: integral membrane proteins that function coordinately with the insulin-like growth factor I receptor to regulate intracellular signaling. Endocrinology 2003; 144:1664-1670.
81. Ogata T, Fukami M. Clinical features in SHOX haploinsufficiency: diagnostic and therapeutic implications. Growth Genet Horm 2004; 20:17-23.
82. Liebezeit BU, Rohrer TR, Singer H, Doerr HG. Tall stature as presenting symptom in a girl with triple X syndrome. J Pediatr Endocrinol Metab 2003; 16:233-235.
83. Marchini A, Marttila T, Winter A, et al. The short stature homeobox protein SHOX induces cellular growth arrest and apoptosis and is expressed in human growth plate chondrocytes. J Biol Chem 2004; 279:37103-37114.
84. Munns CJ, Haase HR, Crowther LM, et al. Expression of SHOX in human fetal and childhood growth plate. J Clin Endocrinol Metab 2004; 89:4130-4135.
85. Remes T, Vaisanen SB, Mahonen A, et al. Aerobic exercise and bone mineral density in middle-aged Finnish men: a controlled randomized trial with reference to androgen receptor, aromatase, and estrogen receptor a gene polymorphisms. Bone 2003; 32:412-420.
86. Xiong DH, Xu FH, Liu PY, et al. Vitamin D receptor gene polymorphisms are linked to and associated with adult height. J Med Genet 2005; 42:228-234.
87. Santoro N, Rankinen T, Perusse L, et al. MC4R marker associated with stature in children and young adults: a longitudinal study. J Pediatr Endocrinol Metab 2005; 18:859-863.
88. Eriksson A-L, Suuriniemi M, Mahonen A, et al. The COMT val158met polymorphism is associated with early pubertal development, height and cortical bone mass in girls. Pediatric Res 2005; 58:71-77.
89. Maheshwari HG, Silverman B, Dupuis J, Baumann G. Phenotype and genetic analysis of a syndrome caused by an inactivating mutation in the growth hormonereleasing hormone receptor: dwarfism of Sindh. J Clin Endocrinol Metab 1998; 83:4065-4074.
90. Hwa V, Little B, Adiyaman P, et al. Severe growth hormone insensitivity resulting from total absence of signal transducer and activator of transcription 5b. J Clin Endocrinol Metab 2005; 90:4260-4266.
91. LeRoith D, Nissley P. Knock your SOCS off. J Clin Invest 2005; 115:233-236.
92. Root AW, Powers PS. Anorexia nervosa presenting as growth retardation in adolescents. J Adol Health Care 1983; 4:25-30.
93. Nathan BM, Palmert MR. Impact of body mass index on growth in boys with delayed puberty. 87th Annual Meeting of the Endocrine Society, San Diego, CA, 2005b, OR43-OR45 (Abstract).
94. De Simone M, Farello G, Palumbo M, et al. Growth charts, growth velocity and bone development in childhood obesity. Int J Obes Relat Metab Disord 1995; 19:851-857.
95. He Q, Karlberg J. BMI during childhood and its association with height gain, timing of puberty, and final height. Pediatr Res 2001; 49:244-251.
96. Umpalchitra V, Adeleye O, Dhuper S, et al. Effects of different degrees of obesity in children and adolescents [abstr]. Pediatric Academic Societies, 2005 Annual Meeting, Washington, D.C., PAS 2005:57:1020.
97. Allen DB, Rose SR, Reiter EO. Normal growth and growth disorders. In: Kappy MS, Allen DB, Geffner ME, eds. Principles and Practice of Pediatric Endocrinology. Springfield: Charles C Thomas, 2005:77-216.
98. Fredriks AM, van Buuren S, Burgmeijer RJ, et al. Continuing positive secular growth change in The Netherlands 1955-1997. Pediatr Res 2000; 47:316-323.
99. Root AW. The tall rapidly growing infant, child and adolescent. Curr Opin Endocrinol Diabetes 2001; 28:6-16.
100. Butenandt O, Bechtold S, Meidert A. Final height in patients with constitutional delay of growth and development from tall statured families. J Pediatr Endocrinol Metab 2005; 18:165-169.
101. Evain-Brion D, Garnier P, Schimpf RM, et al. Growth hormone response to thyrotropin-releasing hormone and oral glucose-loading tests in tall children and adolescents. J Clin Endocrinol Metab 1983; 56:429-432.
102. Iughetti I, Bergomi A, Bernasconi S. Diagnostic approach and therapy of overgrowth and tall stature in childhood. Minerva Pediatr 2003; 55:563-574.
103. Barnard ND, Scialli AR, Bobela S. The current use of estrogens for growth-suppressant therapy in adolescent girls. J Pediatr Adolesc Gynec 2002; 15:23-26.
104. De Waal WJ, Greyn-Fokker MH, Stijnen T, et al. Accuracy of final height prediction and effect of growth-reductive therapy in 362 constitutionally tall children. J Clin Endocrinol Metab 1996; 81:1206-1216.
105. Gruters A, Heidemann P, Schluter H, et al. Effect of different oestrogen doses on final height reduction in girls with constitutional tall stature. Eur J Pediatr 1989; 149:11-13.
106. De Waal WJ, Torn M, de Muinck Kreizer-Schrama SMPF, et al. Long term sequelae of sex steroid treatment in the management of constitutionally tall stature. Arch Dis Child 1995; 73:311-315.
107. Van Ommen C, Fijnvamdraat K, Vulsma T, et al. Acquired protein S deficiency caused by estrogen treatment of tall stature. J Pediatr 1999; 135:477-481.
108. Venn A, Bruinsma G, Werther G, et al. Oestrogen treatment to reduce the adult height of tall girls: long-term effects on fertility. Lancet 2004; 364:1513-1518.
109. Bettendorf M, Heinrich UE, Schonberg DK, Grulich-Henn J. Short-term, high-dose testosterone treatment fails to reduce adult height in boys with constitutional tall stature. Eur J Pediatr 1997; 156:911-915.
110. Traupe H, von Muhlendahl KE, Bramswig J, Happle R. Acne of the fulmins type following testosterone therapy in three excessively tall boys. Arch Dermatol 1988; 124:414-417.
111. Hindmarsh PC, Pringle PJ, Di Silvio L, Brook CGD. A preliminary report on the role of somatostatin analogue (SMS 201-995) in the management of children with tall stature. Clin Endocrinol 1990; 32:83-91.
112. Kopchick JJ, Parkinson C, Stevens EC, PJ Trainer. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocrine Rev 2002; 23:623-646.
113. Hero M, Norjavaara E, Dunkel L. Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases predicted adult height in boys with idiopathic short stature: a randomized controlled trial. J Clin Endocrinol Metab 2005; 90:6396-6402.
114. Kreher NC, Eugster EA, Shankar RR. The use of tamoxifen to improve height potential in short pubertal boys. Pediatrics 2005; 116:1513-1515.
115. Binder G, Grauer ML, Wehner AV, et al. Outcome in tall stature. Final height and psychological aspects in 220 patients with and without treatment. Eur J Pediatr 1997; 156:905-910.
116. Magnusson PK, Gunnell D, Tynelius P, et al. Strong inverse correlation between height and suicide in a large cohort of Swedish men: evidence of early life origins or suicidal behavior? Am J Psychiat 2005; 162:1373-1375.
117. Rasmussen F, Gunnell D, Ekbom A, et al. Birth weight, adult height, and testicular cancer: cohort study of 337, 249 Swedish young men. Cancer Causes Control 2003; 14:595-598.
118. Akintoye SO, Chebli C, Booher S, et al. Characterization of gsp-mediated growth hormone excess in the context of McCune-Albright syndrome. J Clin Endocrinol Metab 2002; 87:5104-5112.
119. Marx SJ, Simonds WF. Hereditary hormone excess: genes, molecular pathways, and syndromes. Endocrine Rev 2005; 26:615-661.
120. Zacharin M. Pediatric management of endocrine complications in McCune-Albright syndrome. J Pediatr Endocrinol Metab 2005; 18:33-41.
121. Karantza M, Geffner M. Growth and growth hormone in children with neurofibromatosis type 1. Growth Genet Horm 2005; 21:33-38.
122. Thorner MO, Perryman RL, Cronin MJ, et al. Somatotroph hyperplasia: successful treatment of acromegaly by removal of a pancreatic islet tumor secreting a growth hormone releasing factor. J Clin Invest 1982; 70:965-977.
123. Zimmerman D, Young WF Jr, Ebersold MJ, et al. Congenital gigantism due to growth hormone-releasing hormone excess and pituitary hyperplasia with adenomatous transformation. J Clin Endocrinol Metab 1993; 76:216-222.
124. Eugster EA, Pescovitz OH. Gigantism. J Clin Endocrinol Metab 1999; 84:4379-4384.
125. Beuschlein F, Strasburger CJ, Siegerstetter V, et al. Acromegaly caused by secretion of growth hormone by a non-Hodgkin’s lymphoma. N Engl J Med 2000; 342: 1871-1876.
126. Schoof E, Dorr HG, Kiess W, et al. Five-year follow-up of a 13-year old boy with a pituitary adenoma causing gigantism-effect of octreotide therapy. Horm Res 2004; 61:184-189.
127. Katznelson L. Diagnosis and treatment of acromegaly. Growth Horm IGF Res 2005; 15:S31-S35.
128. Rix M, Laurberg P, Hoejberg AS, Brock-Jacobsen B. Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl. Eur J Endocrinol 2005; 153: 195-201.
129. Feenstra J, de Herder WW, ten Have SMTH, et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 2005; 365: 1644-1646.
130. den Ouden DT, Kroon M, Hoogland PH. A 43-year old male with untreated panhypopituitarism due to absence of the pituitary stalk: from dwarf to giant. J Clin Endocrinol Metab 2002; 87:5430-5434.
131. Faustini-Fustini M, Balestrieri A, Rochira V, Carani C. The apparent paradox of tall stature with hypopituitarism: new insights from an old story. J Clin Endocrinol Metab 2003; 88:4002-4003.
132. Lazar L, Dan S, Phillip M. Growth without growth hormone: growth pattern and final height of five patients with idiopathic combined pituitary hormone deficiency. Clin Endocrinol 2003; 59:82-88.
133. Phillip M, Moran O, Lazar L. Growth without growth hormone. J Pediatr Endocrinol Metab 2002; 15(suppl 5):1267-1272.
134. Nathan BM, Palmert MR. Regulation and disorders of pubertal timing. Endocrinol Metab Clin NA 2005; 34:617-641.
135. Root AW. Sexual precocity: a historical perspective and update. Fetal Pediatr Pathol 2005; 24:39-62.
136. Palmert MR, Malin HV, Boepple PA. Unsustained or slowly progressive puberty in young girls: initial presentation and long-term follow-up of 20 untreated patients. J Clin Endocrinol Metab 1999; 84:415-423.
137. Sperling MA. Neonatal diabetes mellitus: from understudy to center stage. Curr Opin Pediatr 2005; 17:512-518.
138. Falorni A, Galmacci G, Bini V, et al. Using obese specific charts of height and height velocity for assessment of growth in obese children and adolescents during weight excess reduction. Eur J Clin Nutr 1999; 53:181-188.
139. Veldhuis JD, Iranmanesh A, Ho KKY, et al. Dual defects in pulsatile growth hormone secretion and clearance subserve the hyposomatotropism of obesity in man. J Clin Endocrinol Metab 1991; 72:51-59.
140. Argente J, Caballo N, Barrios V, et al. Multiple endocrine abnormalities of growth hormone and insulin-like growth factor axis in prepubertal children with exogenous obesity: effect of short and long term weight reduction. J Clin Endocrinol Metab 1997; 82:2076-2083.
141. Ballerini MG, Ropelato MG, Domene HM, et al. Differential impact of simple childhood obesity on the components of the growth hormone-insulin-like growth factor (IGF)-IGF binding proteins axis. J Pediatr Endocrinol Metab 2004; 17:749-757.
142. Frystyk J, Vestbo E, Skjaerbaek C, et al. Free insulin-like growth factors in human obesity. Metabolism 1995; 44:37-44.
143. Martha P, Reiter E, Davial N, et al. Serum growth hormone (GH)-binding protein/receptor: an important determinant of GH responsiveness. J Clin Endocrinol Metab 1992; 74:1464-1469.
144. Morava E, Hol FA, Janssen A, Smeitink J. Tall stature and progressive encephalopathy. J Inherit Metab Dis 2003; 26:720-722.
145. Metherell LA, Chapple JP, Cooray S, et al. Mutations in MRAP, encoding a new interacting partner of the ACTH receptor, cause familial glucocorticoid deficiency type 2. Nature Genet 2005; 37:166-170.
146. Cronshaw JM, Matunis MJ. The nuclear pore complex protein ALADIN is mislocalized in triple A syndrome. Proc Nat Acad Sci 2003; 100:5823-5827.
147. Mendonca BB, Leite MV, de Castro M, et al. Female pseudohermaphroditism caused by a novel homozygous missense mutation of the GR gene. J Clin Endocrinol Metab 2002; 87:1805-1809.
148. Sotos JF, Dodge PR, Muirhead D, et al. Cerebral gigantism in childhood: a syndrome of excessively rapid growth with acromegalic features and a non progressive neurologic disorder. N Engl J Med 1964; 27:109-116.
149. Faravelli F. NSD1 mutations in Sotos syndrome. Am J Med Genet Part C 2005; 137C:24-31.
150. Cole TR, Hughes HE. Sotos syndrome: a study of the diagnostic criteria and natural history. J Med Genet 1994; 31:20-32.
151. de Boer L, Srina KG, Karperien M, et al. Genotype-phenotype correlations in patients suspected of having Sotos syndrome. Horm Res 2004; 62:197-207.
152. Tatton-Brown K, Rahman N. Clinical features of NSD-1 positive Sotos syndrome. Clin Dysmorph 2004; 13: 199-2004.
153. Wit J-M, Beemer FA, Barth PG, et al. Cerebral gigantism (Sotos syndrome). Compiled data of 22 cases. Analysis of clinical features, growth and plasma somatomedin. Eur J Pediatr 144:131-140,1985.
154. Cytrynbaum CS, Smith AC, Rubin T, Weksberg R. Advances in overgrowth syndromes: clinical classification to molecular delineation in Sotos syndrome and Beckwith-Wiedemann syndromes. Curr Opin Pediatr 2005; 17:740-746.
155. Buyukgebiz A, Ercal D, Bober E. Sotos syndrome with septo-optic dysplasia. J Pediatr Endocrinol Metab 1996; 9:497-499.
156. Maucen L, Sorge G, Baieli S, et al. Aggressive behavior in patients with Sotos syndrome. Pediatr Neurol 2000; 22:64-67.
157. Gorlin RJ, Cohen MM, Levin LS. Overgrowth syndromes and postnatal onset obesity syndromes. In: Gorlin RJ, Cohen MM, Levin LS, eds. Syndromes of the Head and Neck. 3rd ed. New York: Oxford University Press, 1990:323-352.
158. Ambler GR, Cowell CT, Quigley CA, Silink M. Growth hormone hypersecretion in Sotos’ syndrome? Acta Paediatr 1993; 82:214-216.
159. de Boer L, Hoogerbrugge CM, van Doorn J, et al. Plasma insulin-like growth factors (IGFs), IGF-binding proteins (IGFBPs), acid labile subunit (ALS) and IGFBP-3 proteolysis in individuals with clinical characteristics of Sotos syndrome. J Pediatr Endocrinol Metab 2004; 16: 615-627.
160. LeRoith D, Bondy C, Yakar S, et al. The somatomedin hypothesis: 2001. Endocrine Rev 2001; 22:53-74.
161. Kurotaki N, Stankiewica P, Wakui K, et al. Sotos syndrome common deletion is mediated by directly oriented subunits within inverted Sos-REP low-copy repeats. Hum Molec Genet 2005; 14:535-542.
162. Melchior L, Schwartz M, Duno M. dHPLC screening of the NSD1 gene identifies nine novel mutations-summary of the first 100 Sotos syndrome mutations. Ann Hum Genet 2005; 69:222-226.
163. Visser R, Shimokawa O, Harada N, et al. Identification of a 3.0-kb major recombination hotspot in patients with Sotos syndrome who carry a common 1.9-Mb microdeletion. Am J Hum Genet 2005; 76:52-67.
164. Lupski JR. Genomic disorders: structural features of the genome can lead to DNA rearrangements and human disease traits. Trends Genet 1998; 14:417-422.
165. Tatton-Brown K, Douglas J, Coleman K, et al. Multiple mechanisms are implicated in the generation of 5q35 microdeletions in Sotos syndrome. J Med Genet 2005; 42:307-313.
166. Miyake N, Kurotaki N, Sugawara H, et al. Preferential paternal origin of microdeletions caused by prezygotic chromosome or chromatid rearrangements in Sotos syndrome. Am J Hum Genet 2003; 72:1331-1337.
167. Douglas J, Hanks S, Temple IK, et al. NSD1 mutations are the major cause of Sotos syndrome and occur in some cases of Weaver syndrome but are rare in other overgrowth phenotypes. Am J Hum Genet 2003; 72:132-143.
168. Nagai T, Matsumoto N, Kurotaki N, et al. Sotos syndrome and haploinsufficiency of NSD1: clinical features of intragenic and submicroscopic deletions. J Med Genet 2003; 40:285-289.
169. Tatton-Brown K, Douglas J, Coleman K, et al. Genotype-phenotype associations in Sotos syndrome: an analysis of 266 individuals with NSD1 aberrations. Am J Hum Genet 2005; 77:193-204.
170. Rayasam GV, Wendling O, Angrand PO, et al. NSD1 is essential for early post-implantation development and has a catalytically active SET domain. EMBO J 2003; 22:3153-3163.
171. Turkman S, Gillessen-Kaesbach G, Meinecke P, et al. Mutations in NSD1 are responsible for Sotos syndrome, but are not a frequent finding in other overgrowth phenotypes. Eur J Hum Genet 2003; 11:858-865.
172. Opitz JM, Weaver DW, Reynolds JF, Jr. The syndromes of Sotos and Weaver: reports and review. Am J Med Genet 1998; 79:294-304.
173. Proud VK, Braddock SR, Cook L, et al. Weaver syndrome: autosomal dominant inheritance of the disorder. Am J Med Genet 1998; 79:305-310.
174. Combs JT, Grant JA, Brandt IK. New syndrome of hypoglycemia. Association with visceromegaly, macroglossia, microcephaly and abnormal umbilicus. N Engl J Med 1966; 275:236-243.
175. Munns CFJ, Batch JA. Hyperinsulinism with Beckwith-Wiedemann syndrome. Arch Dis Child Fetal Neonatal Ed 2001; 84:F67-F69.
176. Weng EY, Moeschler JB, Graham JM, Jr. Longitudinal observations on 15 children with Wiedemann-Beckwith syndrome. Am J Med Genet 1995; 56:366-373.
177. Weksberg R, Shuman C, Smith AC. Beckwith-Wiedemann syndrome. Am J Med Genet Part C 2005; 137C:12-23.
178. Reish O, Lerer I, Amiel A, et al. Wiedemann-Beckwith syndrome: further prenatal characterization of the condition. Am J Med Genet 2002; 107:209-213.
179. Weng E, Mortier G, Graham J. Beckwith-Wiedemann syndrome. Clin Pediatr 1995; 34:317-326.
180. Chitayat D, Rothchild A, Ling E, et al. Apparent postnatal onset of some manifestations of the Wiedemann-Beckwith syndrome. Am J Med Genet 1990; 36:434-439.
181. Gerver WJ, Menheere PP, Schaap C, et al. The effects of a somatostatin analogue on the metabolism of an infant with Beckwith-Wiedemann syndrome and hyperinsulinaemic hypoglycaemia. Eur J Pediatr 1991; 150:634-637.
182. Lteif AN, Schwenk WF. Hypoglycemia in infants and children. Endocrinol Metab Clin NA 1999; 28:619-646.
183. Bliek J, Gicquel C, Maas S, et al. Epigenotyping as a tool for the prediction of tumor risk and tumor type in patients with Beckwith-Wiedemann syndrome (BWS). J Pediatr 2004; 145:796-799.
184. Li M, Squire JA, Weksberg R. Molecular genetics of Beckwith-Wiedemann syndrome. Curr Opin Pediatr 1997; 9:623-629.
185. Brown SW, Villar AJ, Bickmore W, et al. Imprinting mutation in the Beckwith-Wiedemann syndrome leads biallelic IGF-2 expression through an H19-independent pathway. Hum Molec Genet 1996; 5:2027-2032.
186. Slavotinek A, Gaunt L, Donnai D. Paternally inherited duplications of 11p15.5 and Beckwith-Wiedemann syndrome. Med Genet 1997; 34:819-826.
187. Bentov I, Werner H. IGF, IGF receptor and overgrowth syndromes. Pediatr Endocrinol Rev 2004; l:352-360.
188. Dutly F, Baumer A, Kayserili H, et al. Seven cases of Wiedemann-Beckwith syndrome including the first reported case of mosaic paternal isodisomy along the whole chromosome ll. Am J Med Genet 1998; 79:347-353.
189. Jacob S, Moley KH. Gametes and embryoepigentic reprogramming affect developmental outcome: implication for assisted reproductive technologies. Pediatr Res 2005; 58:437-446.
190. Schubeler D, Elgin SCR. Defining epigenetic states through chromatin and RNA. Nature Genet 2005; 37: 917-916.
191. Ekstrom TJ. Parental imprinting and the IGF-2 gene. Horm Res 1994; 42:176-181.
192. DeBaun MR, Niemitz EL, McNeil DE, et al. Epigenetic alterations of H19 and LIT1 distinguish patients with Beckwith-Wiedemann syndrome with cancer and birth defects. Am J Hum Genet 2002; 70:604-611.
193. Baujat G, Rio M, Rossignol S, et al. Paradoxical NSD1 mutations in Beckwith-Wiedemann syndrome and 11p15 anomalies in Sotos syndrome. Am J Hum Genet 2004; 74:715-720.
194. DeBaun ME, Niemitz EL, Feinberg AP. Association of in vitro fertilization with Beckwith-Wiedemann syndrome and epigenetic alterations of LIT1 and H19. Am J Hum Genet 2003; 72:156-160.
195. Gicquel C, Rossignol S, Cabrol S, et al. Epimutation of the telomeric imprinting center region on chromosome 11p15 in Silver-Russell syndrome. Nature Genet 2005; 37: 1003-1007.
196. Li X, Nong Z, Ekstrom C, et al. Disrupted IGF-2 promoter control by silencing of promoter Pl in human hepatocellular carcinoma. Cancer Res 1997; 57:2048-2054.
197. Vu TH, Hoffman A. Alterations in the promoterspecific imprinting of the insulin-like growth factor-II gene in Wilm’s tumor. J Biol Chem 1996; 271: 9014-9023.
198. Henneveld HT, van Lingen RA, Hamel BCJ, et al. Perlman syndrome: four additional cases and review. Am J Med Genet 1999; 86:439-446.
199. Chiao E, Fisher P, Crisponi L, et al. Overgrowth of a mouse model of the Simpson-Golabi-Behmel syndrome is independent of IGF signaling. Devel Biol 2002; 243:185-206.
200. Song HH, Shi W, Xiang YY, Filmus J. The loss of glypican-3 induces alterations in Wnt signaling. J Biol Chem 2005; 280:2116-2125.
201. Marsh DJ, Kum JB, Lunetta KL, et al. PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Hum Molec Genet 1999; 8:1461-1472.
202. Moretti-Ferreira D, Koiffmann CP, Souza DH, et al. Macrocephaly, multiple lipomas and hemangiomata (Bannayan-Zonana syndrome): genetic heterogeneity or autosomal dominant locus with at least two different allelic forms? Am J Med Genet 1989; 34: 548-551.
203. Cohen MM, Jr. Mental deficiency, alterations in performance and CNS abnormalities in overgrowth syndromes. Am J Med Genet (Part C: Semin Med Genet) 2003; 117C:49-56.
204. Ahmed SF, Marsh DJ, Weremowicz S, et al. Balanced translocation of 10q and 13q, including the PTEN gene, in a boy with a human chorionic gonadotropin-secreting tumor and the Bannayan-Riley-Ruvacalba syndrome. J Clin Endocrinol Metab 1990; 84:4665-4670.
205. Hendriks YMC, Verhallen JTCM, van der Smagt JJ, et al. Bannayan-Riley-Ruvalcaba syndrome: further delineation of the phenotype and management of PTEN mutation-positive cases. Familial Cancer 2003; 2:79-85.
206. Liaw D, Marsh DJ, Li J, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nature Genet 1997; 16:64-67.
207. Longy M, Coulon V, Duboue B, et al. Mutations of PTEN in patients with Bannayan-Riley-Ruvacalba phenotype. J Med Genet 1998; 35:886-889.
208. Zori RT, Marsh DJ, Graham GE, et al. Germline PTEN mutation in a family with Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome. Am J Med Genet 1998; 80:399-402.
209. Waite KA, Eng C. Protean PTEN: form and function. Am J Hum Genet 2002; 70:829-844.
210. Stambolic V, Suzuki A, de la Pompa JL, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998; 95:29-39.
211. Zhou X-P, Waite KA, Pilarski R, et al. Germline PTEN promoter mutations and deletions in Cowden/Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase/Akt pathway. Am J Hum Genet 2003; 73:404-411.
212. Cohen MM Jr. Proteus syndrome: an update. Am J Med Genet 2005; 137:38-52.
213. Jamis-Dow CA, Turner J, Biesecker LG, Choyke PL. Radiologic manifestations of Proteus syndrome. Radio-Graphics 2004; 24:1051-1068.
214. Happle R. Cutaneous manifestations of lethal genes. Hum Genet 1986; 72:280.
215. Dumic M, Vukelic D, Plavsic V, et al. Nevo syndrome. Am J Med Genet 1998; 76:67-70.
216. Giunta C, Randolph A, Al-Gazali L, et al. Nevo syndrome is allelic to the kyphoscoliotic type of the Ehlers-Danlos syndrome (EDS VIA). Am J Hum Genet 2005; 133A: 158-164.
217. Pyeritz RE. The Marfan syndrome. Ann Rev Med 2000; 51:481-510.
218. Aoyama T, Francke U, Dietz HC, et al. Quantitative differences in biosynthesis and extracellular deposition of fibrillin in cultured fibroblasts distinguish five groups of Marfan syndrome patients and suggest distinct pathogenetic mechanisms. J Clin Invest 1994; 94:130-137.
219. Erkula G, Jones KB, Sponsellar PD, et al. Growth and maturation in Marfan syndrome. Am J Med Genet 2002; 109:100-115.
220. Biery NJ, Eldahah ZA, Moore CS, et al. Revised genomic organization of FBNl and significance for regulated gene expression. Genomics 1999; 56:70-77.
221. Sakai LY, Keene DR, Engvall E. Fibrillin, a new 350-kD glycoprotein, is a component of extracellular microfibrils. J Cell Biol 1986; 103:2499-2509.
222. Handford PA, Downing AK, Reinhardt DP, et al. Fibrillin: from domain structure to supramolecular assembly. Matrix Biol 2000; 19:457-470.
223. Loeys BL, Matthys DM, De Paepe AM. Genetic fibrillinopathies: new insights in molecular diagnosis and clinical management. Acta Clin Belg 2002; 58:233-241.
224. Gigante A, Chillemi C, Greco F. Changes of elastic fibers in musculoskeletal tissues of Marfan syndrome: a possible mechanism of joint laxity and skeletal overgrowth. J Pediatr Orthop 1999; 19:283-288.
225. Nollen GJ, Mulder BJ. What is new in Marfan syndrome? Intern J Cardiol 2004; 97(suppl 1):103-108.
226. Gray JR, Davies SJ. Marfan syndrome. J Med Genet 1996; 33:403-408.
227. Silverman DI, Gray J, Roman MJ, et al. Family history of severe cardiovascular disease in Marfan syndrome is associated with increased aortic diameter and decreased survival. J Am Col Cardiol 1995; 26:1062-1067.
228. Roman MJ, Devereux RB, Kramer-Fox R, et al. Two dimensional echocardiographic aortic root dimensions in normal children and adults. Am J Cardiol 1989; 64:507-512.
229. Shores J, Berger KR, Murphy EA, et al. Progression of aortic dilation and the benefit of long-term beta-adrenergic blockade in Marfan’s syndrome. N Engl J Med 1994; 330:1335-1341.
230. Dietz HC, Pyeritz RE. Marfan syndrome and related disorders. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Diseases. 9th ed. McGraw-Hill, 2001:5287-5311.
231. Rozendaal L, le Cessie S, Wit JM, et al. Growth-reductive therapy in children with Marfan syndrome. J Pediatr 2005; 147:674-679.
232. Sotos JF. Overgrowth. Clin Pediatr 1997; 36:89-103.
233. Mudd SH, Skovby F, Levy HL, et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet 1985; 37:1-31.
234. Topaloglu AK, Sansaricq C, Snyderman SE. Influence of metabolic control on growth in homocystinuria due to cystathionine b-synthase deficiency. Pediatr Res 2001; 49:796-798.
235. Fritzer-Szekeres M, Blom HJ, Boers GH. Growth promotion by homocysteine but not by homocysteic acid: a role for excessive growth in homocystinuria or proliferation in hyperhomocysteinemia? Biochim Biophys Acta 1998; 1407:1-6.
236. Mudd SH, Levy HL, Skovby F. Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS, Valle D. The Metabolic Basis of Inherited Disease. 6th ed. New York: McGraw-Hill, 1989:693-734.
237. Woodruff JM. Pathology of tumors of the peripheral nerve sheath in type l neurofibromatosis. Am J Med Genet 1999; 89:23-30.
238. Arun D, Gutmann DH. Recent advances in neurofibromatosis type l. Curr Opin Neurol 2004; 17:101-105.
239. Listernick R, Charrow J. Neurofibromatosis-1 in childhood. Adv Dermatol 2004; 20:75-115.
240. Listernick R, Louis DN, Pacer RJ, et al. Optic pathway gliomas in children with neurofibromatosis l: consensus statement from the NFl Optic Pathway Glioma Task Force. Ann Neurol 1997; 41:143-149.
241. Lewis RA, Riccardi VM. Von Recklinghausen neurofibromatosis: incidence of iris hamartomata. Ophthalmology 1981; 88:348-354.
242. Huson SM, Hughes RAC. The Neurofibomatoses: A Pathogenetic and Clinical Overview. London: Chapman and Hall, 1994.
243. Rubenstein A, Wallerstein R, Arlon A, et al. Lack of correlation of megalencephaly with learning disability in disseminated neurofibromatosis. Am J Hum Genet 1985; 37:A74.
244. Tong J, Hanna F, Zhu Y, et al. Neurofibromin regulates G protein-stimulated adenylyl cyclase activity. Nature Neurosci 2002; 5:95-96.
245. de Vries BBA, Robinson H, Stolte-Dijkstra I, et al. General overgrowth in the fragile X syndrome: variability in the phenotypic expression of the FMR1 gene mutation. J Med Genet 1995; 32:764-769.
246. Crawford DC, Acuna JM, Sherman SL. FMRl and the fragile X syndrome: human genome epidemiology review. Genet Med 2001; 3:359-371.
247. Mandel JL, Biancalana V. Fragile X mental retardation syndrome: from pathogenesis to diagnostic issues. Growth Horm IGF Res 2004; 14:S158-S165.
248. Verheij C, Bakker CE, de Graaff E, et al. Characterization and localization of the FMR-1 gene product associated with fragile X syndrome. Nature 1993; 363:722-724.
249. Fu YH, Kuhl DP, Pizzuti A, et al. Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. Cell 1991; 67:1047-1058.
250. Sherman SL, Morton NE, Jacobs PA, et al. The marker (X) syndrome: a cytogenetic and genetic analysis. Ann Hum Genet 1984; 48:21-37.
251. Laird CD. Possible erasure of the imprint on a fragile X chromosome when transmitted by a male. Am J Med Genet 1991; 38:391-395.
252. Tabolacci E, Pietrobono R, Moscato U, et al. Differential epigenetic modifications in the FMR1 gene of the fragile X syndrome after reactivating pharmacological treatments. Eur J Hum Genet 2005; 13:641-648.
253. Willemsen R, Oostra BA, BassellGJ, Dictenberg J. The fragile X syndrome: frommolecular genetics to neurobiology. Ment Retard Dev Disabil Res Rev 2004; 10:60-67.
254. Gedeon AK, Baker E, Robinson H, et al. Fragile X syndrome without CCG amplification has an FMRl deletion. Nature Genet 1992; 1:341-344.
255. Tamanini F, Bontekoe C, Bakker CE, et al. Different targets for the fragile X-related proteins revealed by their distinct nuclear localizations. Hum Molec Genet 1999; 8:863-869.
256. Wilson HL, Wong ACC, Shaw SR, et al. Molecular characterization of the 22q13 deletion syndrome supports the role of haploinsufficiency of SHANK3/PROSAP2 in the major neurological symptoms. J Med Genet 2003; 40:575-584.